Psilocybin & Psychedelic Terminology Glossary

Accurate language matters enormously in discussions of psychedelic substances — both for safety and for intellectual honesty. Using the wrong term (calling a microdose a macrodose, or confusing psilocybin with psilocin) can lead to genuine misunderstanding with real consequences. This glossary aims to establish precise, shared definitions for the vocabulary used across research, harm reduction, mycology, and community contexts.

Terms are grouped thematically below. Use the navigation links to jump to a section, or scroll through the full glossary.

Chemistry & Pharmacology

Psilocybin (sye-loh-SY-bin)

The primary psychoactive compound found in "magic mushrooms." Chemically, psilocybin is a tryptamine alkaloid with the systematic name O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine. It is a prodrug — biologically inactive on its own — that is rapidly dephosphorylated by alkaline phosphatase enzymes in the body to produce the active compound, psilocin. Psilocybin content in dried Psilocybe cubensis typically ranges from 0.37–1.30% by dry weight, though this varies substantially between strains and growing conditions. First isolated by Albert Hofmann at Sandoz Laboratories in 1958.

Psilocin (SY-loh-sin)

The active metabolite of psilocybin, produced in the body after dephosphorylation. Psilocin directly binds to serotonin receptors, particularly the 5-HT2A receptor, producing psychedelic effects. Psilocin is more chemically unstable than psilocybin — it oxidises readily (the blue-bruising reaction in psilocybin mushrooms is caused by psilocin oxidation). This is why mushrooms should be dried rapidly and stored away from light and heat.

Prodrug

A pharmacologically inactive compound that is converted to an active drug by the body's metabolic processes. Psilocybin is a prodrug for psilocin. The significance for harm reduction is that the route of administration affects this conversion — sublingual administration bypasses some gut processing, while oral administration relies on intestinal alkaline phosphatase for conversion.

5-HT2A Receptor (five-aitch-tee-two-ay)

The primary serotonin receptor subtype responsible for the psychedelic effects of psilocin (and other classic psychedelics such as LSD and mescaline). 5-HT2A receptors are distributed throughout the brain, with particularly high concentrations in the prefrontal cortex, anterior cingulate cortex, and visual cortex. Activation of 5-HT2A receptors by psilocin is believed to underlie the hallucinogenic, mystical, and anti-depressive effects observed in research. The receptor belongs to the G protein-coupled receptor (GPCR) superfamily.

Alkaloid

A class of naturally occurring organic compounds containing nitrogen atoms, typically with significant pharmacological activity. Psilocybin and psilocin are indole alkaloids of the tryptamine class. Other psychedelic alkaloids include DMT (dimethyltryptamine), mescaline, ibogaine, and the ergoline alkaloids (e.g., LSD derivatives).

Baeocystin and Norbaeocystin

Minor tryptamine compounds found alongside psilocybin in many Psilocybe species. Their individual pharmacological activity in humans is debated, but they may contribute to the overall effect profile of different mushroom strains and species — a possible component of the "entourage effect" hypothesis in psychedelic pharmacology.

Aeruginascin

A quaternary ammonium compound found in Inocybe aeruginascens and certain other species. Believed to modulate the effects of psilocybin, potentially contributing to a more euphoric character in those species.

Half-Life

The time it takes for the concentration of a substance in the body to reduce by half. Psilocin has a plasma half-life of approximately 50 minutes to 3 hours. This explains why psilocybin experiences typically last 4–6 hours: by the time 3–4 half-lives have elapsed, psilocin concentrations have dropped to levels that produce minimal perceptual effects.

Neuroscience & Brain Science

Default Mode Network (DMN)

A network of brain regions that is active during rest, self-referential thinking, rumination, and mind-wandering. Regions of the DMN include the medial prefrontal cortex, posterior cingulate cortex, angular gyrus, and lateral temporal cortex. Psilocybin is known to dramatically reduce activity and functional connectivity within the DMN, an effect associated with the dissolution of the ordinary sense of self. Overactivity of the DMN has been implicated in depression, anxiety, and addiction, which may partly explain psilocybin's therapeutic effects.

Entropic Brain Hypothesis

A neuroscientific theory proposed by Robin Carhart-Harris and colleagues, suggesting that psychedelics increase "neural entropy" — the complexity and unpredictability of brain activity patterns. In this model, the normal waking brain occupies an intermediate zone between too much order (rigid, ruminative states) and too much disorder (psychosis). Classic psychedelics move the brain toward higher entropy, producing more flexible, less constrained patterns of thought and perception.

Neuroplasticity

The brain's capacity to reorganise itself by forming new neural connections. Psilocybin has been shown in both animal studies and some human research to promote neuroplasticity, including increased dendritic branching and synaptogenesis in the prefrontal cortex. This is proposed as a mechanism for the rapid and lasting antidepressant effects seen in clinical trials — the brain may become temporarily more "plastic" and open to forming new patterns of thought and behaviour during and after a psilocybin experience.

Serotonergic

Relating to or involving serotonin (5-hydroxytryptamine, or 5-HT). Classic psychedelics like psilocybin are described as serotonergic psychedelics because their primary mechanism of action involves serotonin receptors. This distinguishes them from dopaminergic (e.g., cocaine) or GABAergic (e.g., benzodiazepines) substances.

HPPD (Hallucinogen Persisting Perception Disorder)

A rare condition in which visual phenomena experienced during a psychedelic experience persist or recur after the experience has ended. Symptoms include visual snow, trailing (afterimages from moving objects), geometric patterns, or halos around lights. HPPD can range from barely noticeable to significantly distressing. Risk factors include high doses, frequent use, pre-existing anxiety or depersonalisation disorders, and use during adolescence. Most cases resolve within weeks to months; a small proportion become chronic.

Dosage Terminology

Microdose

A dose of a psychedelic substance that is deliberately sub-perceptual — low enough that no noticeable alteration of consciousness occurs during normal daily activities. For dried Psilocybe cubensis, a microdose is typically in the range of 0.05–0.2 g. The defining criterion is that the user should be able to function normally — work, drive, have conversations — without others being aware they have taken anything. See also: Fadiman Protocol, Stamets Stack.

Threshold Dose

The minimum amount of a substance required to produce any noticeable psychoactive effect. At threshold, effects are subtle but perceptible — a slight mood lift, marginally enhanced sensory perception, mild tingling. For dried P. cubensis, the threshold is typically around 0.25–0.5 g, though individual sensitivity varies considerably. A threshold dose sits between a microdose (sub-perceptual) and a low dose (mild but clear effects).

Low Dose

A dose producing mild, manageable psychedelic effects. For dried P. cubensis, this is approximately 0.5–1.5 g. Effects include mood brightening, mild visual enhancement (slightly more vivid colours), increased sociability, and gentle introspection. Cognitive function is mildly affected but not overwhelmed. Often recommended as a starting point for those new to psilocybin who want to experience the space without intensity.

Moderate Dose

The range most commonly used in clinical trials and for deliberate therapeutic or introspective purposes. For dried P. cubensis, approximately 1.5–3.5 g. Visual phenomena become more pronounced, emotional depth increases, time perception may be significantly altered, and the sense of ordinary self may loosen. Most people consider this a genuine "trip." Challenging experiences become more possible at moderate doses, making set, setting, and sitter presence important.

High Dose

Doses above approximately 3.5 g of dried P. cubensis or equivalent. At high doses, ego dissolution and mystical experiences become more likely. Clinical research on psilocybin for depression typically uses 20–30 mg of synthetic psilocybin, roughly equivalent to 3–4 g of average potency cubensis. High doses are associated with a significantly increased risk of overwhelming or challenging experiences and should not be taken without considerable experience and appropriate preparation.

Heroic Dose

A term popularised by ethnobotanist Terence McKenna for very large doses — typically 5 g or more of dried P. cubensis. McKenna advocated for heroic doses as a path to profound psychedelic experience and ego dissolution. From a harm reduction perspective, heroic doses carry substantially elevated risk of overwhelming psychological experiences, dissociation, and in rare cases, behavioural risk (attempting to leave a safe space, for example). They are generally not recommended without significant prior experience, a trusted sitter, and a carefully prepared set and setting.

Macrodose

Any dose above the microdose range that produces noticeable psychoactive effects. Often used colloquially to contrast with microdose, referring to any full experience dose. Not a term with a fixed numerical definition.

Tolerance

Reduced response to a substance following repeated use, requiring higher doses to produce the same effect. Psilocybin produces rapid and marked tolerance — within days of use. After a full-dose experience, 5-HT2A receptors are downregulated, meaning a second dose taken the next day would require approximately 2–3x the original amount to produce the same effect. Tolerance typically clears within 1–2 weeks of abstinence.

Cross-Tolerance

Tolerance developed for one substance that also reduces the effect of a pharmacologically related substance. Classic psychedelics (LSD, psilocybin, mescaline, DMT) share cross-tolerance, meaning use of one produces temporary tolerance to the others. Notably, MDMA does not share cross-tolerance with classic psychedelics (different mechanism of action).

Ceiling Effect

A pharmacological phenomenon in which increasing the dose beyond a certain point produces no additional increase in the desired effect. Psilocybin and most classic psychedelics have a ceiling effect — at very high doses, additional material does not produce proportionally more intense experiences, though it may increase duration and the risk of adverse effects.

Experience & Phenomenology

Set and Setting

The two most important non-pharmacological determinants of a psychedelic experience. Set (short for mindset) refers to the user's mental state, intentions, expectations, and emotional history going into the experience. Setting refers to the physical environment and social context — who is present, whether the space feels safe, whether there is access to nature or a comfortable indoor space. The concept was first systematically articulated by Timothy Leary, Ralph Metzner, and Richard Alpert in the 1960s, and is now fundamental to clinical psychedelic research and harm-reduction practice.

Ego Dissolution / Ego Death

The temporary dissolution of the ordinary sense of being a bounded, separate self. At sufficient doses, psilocybin can produce a state in which the distinction between "self" and "world" temporarily ceases to be apparent. This experience ranges from mildly pleasurable loosening of self-boundaries to complete and sometimes frightening dissolution of the sense of personal identity. In clinical research, ego dissolution is measured by scales such as the Ego Dissolution Inventory (EDI) and is associated with mystical experience, emotional processing, and therapeutic outcomes.

Mystical Experience

A profound altered state characterised by a sense of unity, sacredness, noetic quality (a sense of gaining genuine knowledge), transcendence of time and space, deeply felt positive mood, and ineffability (difficulty putting the experience into words). The Mystical Experience Questionnaire (MEQ) is the primary research instrument for measuring this construct. Higher scores on the MEQ following psilocybin administration have been consistently associated with better therapeutic outcomes in depression, anxiety, and addiction research.

Oceanic Boundlessness

One of the primary dimensions of psychedelic experience captured by the 5D-ASC (Altered States of Consciousness) scale, characterised by blissful feelings of expanded self, unity with the environment, and dissolution of normal ego boundaries. Associated with positive affect and spiritual experience.

Challenging Experience

A psychedelic experience that is difficult, distressing, frightening, or emotionally overwhelming, but not necessarily harmful. Challenging experiences are common even at moderate doses and may involve anxiety, paranoia, confusion, disturbing imagery, or confrontation with difficult psychological material. From a harm-reduction and clinical perspective, challenging experiences are not automatically "bad" — many people report that their most difficult sessions were also the most meaningful and therapeutically significant in the long run, particularly when integrated with appropriate support.

Bad Trip

Informal term for a predominantly negative, frightening, or dysphoric psychedelic experience. Harm-reduction guidance emphasises that "bad trips" are not inevitable at any dose, are most commonly precipitated by inappropriate set, setting, or dose, and can often be navigated with the help of a skilled sitter. The Fireside Project, Zendo Project, and DanceSafe all provide support resources for people in the midst of difficult experiences.

Integration

The process of making meaning from a psychedelic experience and incorporating insights, emotions, and realisations into everyday life. Integration is considered by most researchers and practitioners to be as important as the session itself. Integration practices include journalling, creative expression, discussion with a therapist or integration coach, meditation, and community sharing. Without integration, insights from an experience may fade rapidly or may not translate into lasting behavioural or psychological change.

Trip Report

A written or verbal account of a psychedelic experience, documenting dose, setting, onset, effects, duration, and aftermath. Trip reports are foundational documents in psychedelic harm-reduction communities, providing experiential data for other users and contributing to the collective knowledge base. Platforms such as Erowid maintain archives of hundreds of thousands of trip reports.

Afterglow

The period following a psilocybin experience — typically 1–3 days — characterised by elevated mood, increased emotional openness, enhanced gratitude, and a sense of clarity or calm. The afterglow is believed to represent a period of neuroplastic opportunity in which new patterns of thinking and behaviour are more easily established, making it an important time for integration work.

Harm Reduction Concepts

Harm Reduction

A public health philosophy and set of practical strategies designed to reduce the negative consequences associated with drug use, without requiring abstinence. In the psychedelic context, harm reduction includes accurate dosing guidance, sitter training, crisis support services, drug checking, and public education. Harm reduction does not morally endorse drug use, but prioritises safety for people who will use substances regardless of legal status.

Trip Sitter

A sober, trusted person who accompanies and supports someone during a psychedelic experience. The sitter's role is not to direct the experience but to ensure physical safety, provide reassurance if the person becomes anxious, and help navigate any challenging moments. Key qualities of a good sitter: experience with the psychedelic state themselves (ideally), calm temperament, knowledge of harm-reduction techniques such as grounding and redirection, and trust between themselves and the person experiencing.

Grounding

Techniques used during a difficult psychedelic experience to reconnect with the present moment and physical reality. Grounding practices include focusing on breath, feeling the texture of surfaces, drinking water, stepping outside, using a weighted blanket, or listening to calming music. Effective grounding can help navigate challenging experiences without requiring pharmacological intervention.

Surrender

A harm-reduction concept and experiential strategy in which the person undergoing a difficult psychedelic experience intentionally stops resisting the experience and allows it to proceed. "Trusting, letting go, and being open" is the mantra used at Johns Hopkins and other clinical sites. Counter-intuitively, attempting to fight or suppress a difficult experience often intensifies it, while surrender and acceptance typically lead to its resolution.

Drug Checking

The practice of testing substances for purity and content before consumption. Reagent tests (Ehrlich, Simon's, etc.) can verify the presence of indole alkaloids (a positive Ehrlich test indicates the likely presence of psilocybin or a similar tryptamine) and can identify dangerous adulterants. Fentanyl test strips, widely used for opioid harm reduction, can also identify fentanyl contamination in samples.

Therapeutic Window

The dose range in which a substance produces desired therapeutic effects without unacceptable side effects or risks. For psilocybin in clinical research, the therapeutic window appears to be in the 20–30 mg range (synthetic psilocybin), roughly equivalent to 3–4 g of dried P. cubensis. Below this range, mystical experiences (associated with therapeutic outcomes) are less likely; above it, the risk of overwhelming experiences increases without proportionate benefit.

Mycology & Growing Terminology

Mycelium (my-SEE-lee-um)

The vegetative part of a fungus, consisting of a network of thread-like structures called hyphae. In mushroom cultivation, mycelium is the main growing body that colonises a substrate before producing fruiting bodies (mushrooms). Healthy mycelium in Psilocybe cultivation is typically white and fluffy. Blue-tinged mycelium indicates psilocin oxidation, which is normal and does not indicate contamination.

Fruiting Body

The reproductive structure of a fungus — what we commonly call the "mushroom." The fruiting body produces and disperses spores. In cultivation, triggering fruiting (the switch from vegetative mycelial growth to fruiting body production) requires specific environmental conditions: a drop in temperature, increased humidity, fresh air exchange, and light stimulation.

Substrate

The growing medium on which mycelium feeds and develops. Common substrates for Psilocybe cubensis cultivation include brown rice flour and vermiculite (BRF, used in PF Tek), sterilised grain (rye, oats, wheat berries), pasteurised straw, and bulk substrates such as coco coir, vermiculite, and hydrated field capacity mixtures. Different substrates affect yield, colonisation speed, and contamination risk.

Colonisation

The process by which mycelium spreads through a substrate, breaking it down enzymatically and using it as a food source. Before fruiting can begin, the substrate must be fully colonised — all available substrate material permeated with mycelium. Partial colonisation leaves uncolonised areas vulnerable to contamination by competing moulds or bacteria.

Contamination (Contam)

The growth of unwanted organisms — bacteria, moulds, or competing fungi — in a substrate intended for mushroom cultivation. Common contaminants include Trichoderma (green mould), Cobweb (usually harmless mycelial variant), and wet rot (bacterial contamination). Contamination control through sterilisation or pasteurisation, clean technique (still-air boxes or laminar flow hoods), and rapid colonisation is the central technical challenge of mushroom cultivation.

Spore

The reproductive unit of fungi, analogous to seeds in plants. In Psilocybe species, spores are produced on the gills of the fruiting body and are purple-black when printed on paper. Spores are used in cultivation (inoculated into a sterile substrate) and for microscopy (legal in most jurisdictions because spores themselves contain no psilocybin). Spore syringes contain spores suspended in sterile water.

Agar

A gelatinous polysaccharide derived from seaweed, used as a solid culture medium in mycology. Agar plates allow mycelium to grow in a visible, controllable environment, enabling the isolation of specific genetic sectors (cloning), the detection and removal of contaminants, and the long-term preservation of genetics. Agar work is considered an advanced cultivation technique.

PF Tek

Short for "Psilocybe Fanaticus Technique," a beginner-friendly cultivation method using small jars of sterilised brown rice flour and vermiculite (BRF). Developed in the early 1990s by a hobbyist known as "Professor Fanaticus," PF Tek involves inoculating BRF jars with a spore syringe, allowing colonisation, then removing the colonised "cakes" to a humidity chamber for fruiting. It remains one of the most popular entry-level techniques due to its simplicity and low equipment requirements.

Monotub

A bulk cultivation technique using a single large plastic storage tote as both the colonisation and fruiting container. A bulk substrate (typically coco coir mixed with vermiculite, or a grain and coco-coir mixture) is inoculated with grain spawn and allowed to colonise and fruit in the same container. Monotubs produce larger yields than PF Tek but require more technical knowledge and cleanliness.

Uncle Ben's Tek

An informal bulk grain tek using pre-sterilised "Uncle Ben's" brand microwave rice packets as the cultivation substrate. The convenience and pre-sterilised nature of these packets makes this a popular beginner technique, though it has largely fallen out of favour as other grain spawn methods have been refined.

Flush

A single fruiting wave from a colonised substrate. Most substrates produce multiple flushes — the first is typically the largest, with subsequent flushes decreasing in yield. Between flushes, the substrate is rehydrated ("dunked" or misted) and allowed to rest.

FAE (Fresh Air Exchange)

The provision of fresh air to a fruiting chamber to prevent CO2 buildup. Mycelium and developing fruiting bodies produce CO2 as a metabolic byproduct. Elevated CO2 levels inhibit fruiting and cause abnormal fruiting body development (elongated, thin stems, small caps). FAE is achieved through passive holes in the fruiting chamber or active fans.

Protocols, Methods & Preparation

Lemon Tek

A preparation method in which ground dried mushrooms are soaked in fresh citrus juice (lemon or lime) for 15–20 minutes before consumption. The citric acid performs a partial conversion of psilocybin to psilocin outside the body, resulting in faster onset (10–30 minutes) and often a more intense but shorter experience. The name derives from the use of lemon juice and the term "tek" (technique). See Recipes for full preparation guidance.

Fadiman Protocol

A microdosing schedule developed by psychedelic researcher James Fadiman, described in his 2011 book The Psychedelic Explorer's Guide. The protocol involves taking a microdose on Day 1, observing effects on Day 2 (transition day), resting on Day 3, then repeating. The one-day-on / two-days-off rhythm is designed to prevent tolerance build-up while providing regular benefit. Most Fadiman Protocol practitioners use the protocol for 4–8 weeks then take a break.

Stamets Stack

A microdosing regimen proposed by mycologist Paul Stamets, combining a microdose of psilocybin mushrooms with lion's mane mushroom (Hericium erinaceus) and niacin (vitamin B3). The rationale: psilocybin provides neuroplasticity, lion's mane promotes nerve growth factor production, and niacin acts as a "flush" to drive the other compounds into peripheral tissues. The combination is hypothesised to support long-term neurological health, though direct clinical evidence for this specific combination remains limited. Schedule: 5 days on, 2 days off.

SWIM

Abbreviation for "Someone Who Isn't Me," a rhetorical device widely used in online drug discussion forums to distance the author from first-person admission of illegal activity. "SWIM tried lemon tek at 2g" means "I tried lemon tek at 2g." The term is now generally considered outdated and unhelpful, as it provides no legal protection while reducing the authenticity of harm-reduction information.

Organisations & Research Bodies

MAPS (Multidisciplinary Association for Psychedelic Studies)

A non-profit research and educational organisation founded in 1986 by Rick Doblin, focused on developing psychedelic and marijuana medicines through FDA-approved Phase 3 clinical trials. Best known for pioneering MDMA-assisted therapy for PTSD (which received Breakthrough Therapy designation from the FDA in 2017) and conducting psilocybin research. MAPS has been instrumental in establishing the legal and scientific framework for psychedelic medicine in the United States.

DanceSafe

A harm reduction organisation founded in 1998, primarily known for providing drug checking services at music events. DanceSafe volunteers test substances for adulterants and provide educational information about drug effects and safer use. Their drug checking kits, including Ehrlich reagent tests (which turn purple in the presence of indole alkaloids such as psilocybin), are widely used for basic verification of substance identity.

Zendo Project

A harm reduction organisation that provides psychedelic peer support at festivals and events, operating within a carefully designed "Zendo" (safe space) structure. Trained volunteer "sitters" guide people through difficult psychedelic experiences using non-directive, person-centred support. The Zendo model has been widely adopted across music festivals and psychedelic conferences worldwide.

Fireside Project

A non-profit psychedelic peer support line (1-623-473-7433, or text "FIRESIDE") that provides free, confidential support for people having difficult psychedelic experiences or processing experiences after the fact. Available in the US. Founded in 2021, the Fireside Project trains volunteers in psychedelic crisis support and integration counselling.

HCRN (Harm Reduction Coalition Network)

A broader harm reduction network providing education, training, and policy advocacy. While not psychedelic-specific, the HCRN's frameworks for non-judgmental, evidence-based drug education underpin much of the community-based harm-reduction work in the psychedelic space.

Johns Hopkins Center for Psychedelic and Consciousness Research

The first centre in the United States dedicated to research on psychedelic substances, opened in 2019 at Johns Hopkins University School of Medicine. Led by Matthew Johnson and Roland Griffiths (1943–2023), the centre has produced landmark studies on psilocybin for treatment-resistant depression, addiction, and end-of-life anxiety. Roland Griffiths' 2006 study in Psychopharmacology is widely credited with relaunching serious scientific investigation of psilocybin after the decades-long prohibition period.

Imperial Centre for Psychedelic Research

A research centre at Imperial College London, founded in 2019 and led by Robin Carhart-Harris. Produced foundational neuroimaging research on psilocybin's effects on the brain (including the default mode network discovery), as well as early clinical trials of psilocybin for depression. Carhart-Harris moved to the University of California San Francisco in 2021, where the research continues.

Common Species & Strain Names

Golden Teacher

One of the most popular and widely cultivated strains of Psilocybe cubensis, known for its moderate potency, reliable fruiting, and forgiving cultivation characteristics. Named for its golden-capped appearance and the reputation for producing "teaching" experiences — introspective, reflective sessions rather than intensely visual ones. A standard entry point for new cultivators and new users alike.

B+ (Be Positive)

A robust, high-yielding P. cubensis strain particularly favoured for its ease of cultivation and warm, social experiential character. Produces large fruiting bodies. Moderate potency. Among the most widely available strains in the amateur cultivation community.

Penis Envy (PE)

A distinctive P. cubensis strain characterised by unusually dense, thick-stemmed fruiting bodies with small, often incompletely developed caps. Generally considered one of the most potent cubensis strains, with higher-than-average psilocybin concentrations. PE strains are harder to cultivate than standard cubensis and produce lower yields, but are sought by experienced users for their potency. Origin attributed to Terence McKenna and Steven Pollock, developed in the 1970s.

Wavy Caps (Psilocybe cyanescens)

A wood-loving species native to the Pacific Northwest and introduced to Europe, known for its distinctly wavy-edged caps. Significantly more potent than P. cubensis — typically 2–3x higher in psilocybin content. Found growing on wood chips in urban environments. Its higher potency means that dose equivalents compared to cubensis must be carefully recalibrated.

Liberty Cap (Psilocybe semilanceata)

One of the most common wild psilocybin mushrooms in the UK and northern Europe, found growing in grasslands (particularly those grazed by sheep or cattle) in autumn. Distinguished by its conical, nipple-tipped cap and olive-brown colour. Highly potent for its small size, with psilocybin concentrations often higher than cubensis. Foraging for P. semilanceata requires confident identification to avoid confusion with non-psilocybin grassland species.

Flying Saucer (Psilocybe azurescens)

Considered one of the most potent psilocybin mushroom species, with psilocybin content reported up to 1.78% dry weight. Native to a small area of the US Pacific coast (Oregon, Washington). Caramel-brown, broad-capped fruiting bodies found on coastal dunes and in wood-rich soil near the ocean in autumn and winter. Extremely potent — dose ranges are dramatically lower than P. cubensis.

Navigate the Terminology Hub

FAQ

1. Why separate slang from scientific terms? To reduce confusion and keep safety guidance precise.
2. Can terms vary by region? Yes — regional variants are noted where relevant.
3. How do I pronounce Latin names? Each scientific entry includes a simple phonetic cue where helpful.
4. Are cultural terms always appropriate to use? Not always — some are context-bound; consult our Cultural Terms page for guidance.
5. Can I request additions? Yes — submit suggestions with sources and context via our About page.
6. What is the difference between psilocybin and psilocin? Psilocybin is the prodrug found in mushrooms; psilocin is the active compound produced when the body converts psilocybin. Psilocin directly activates 5-HT2A receptors.
7. Is "magic mushrooms" an acceptable term? It is widely understood but considered informal. In educational and clinical contexts, "psilocybin mushrooms" or the species name is preferred for precision.
8. What does "cracker dry" mean? A standard used by cultivators to describe mushrooms that are fully desiccated — they snap cleanly rather than bending. This is the appropriate dryness for storage.
9. What does "blue bruising" indicate? Bruising or bluing when mushroom tissue is damaged is caused by psilocin oxidation. It is a useful (though not conclusive) indicator of psilocybin content, but should not be used as the sole identification criterion.
10. What is neuroplasticity and why does psilocybin affect it? Neuroplasticity is the brain's ability to form new connections. Psilocybin promotes neuroplasticity through 5-HT2A receptor activation and downstream effects on BDNF (brain-derived neurotrophic factor). This may underlie the rapid and lasting changes in thinking patterns observed after psilocybin experiences.